The medications Ozempic and Wegovy, initially developed to manage type 2 diabetes and obesity, are generating significant interest for a surprising potential benefit: the treatment of addiction. While these GLP-1 (glucagon-like peptide-1) receptor agonists have become widely known for their efficacy in weight loss – with an estimated one in eight Americans now having used them – growing anecdotal evidence and preliminary research suggest they may reduce cravings and compulsive behaviors associated with a range of addictive disorders. This emerging field of study offers a potentially novel approach to tackling addiction, a complex health issue affecting millions globally.
Reports from patients and clinicians indicate a reduction in cravings not only for substances like alcohol and illicit drugs, but too for behaviors considered addictive, such as compulsive gambling and excessive online shopping. These observations, initially dismissed as coincidental, have prompted scientific investigation and the initiation of clinical trials to rigorously assess the efficacy and safety of GLP-1 drugs in addiction treatment. The potential impact is substantial, given that more than 4,400 lawsuits have been filed against manufacturers of these drugs alleging serious side effects, as reported by USA Today.
The Brain’s Reward System and GLP-1 Agonists
Dr. Dhruv Khullar, a physician and medical correspondent for The New Yorker, has been closely following this development. In an article published February 9th, titled “Can Ozempic Cure Addiction?”, Khullar interviewed scientists and individuals experiencing these effects firsthand. He expressed a growing belief in the potential of these molecules, stating to David Remnick that he had become “more and more bullish on the idea that these are actually going to be really important molecules for the treatment of addiction.”
The mechanism behind this potential therapeutic effect is rooted in the way GLP-1 drugs interact with the brain. GLP-1 is a naturally occurring hormone produced in the gut that regulates appetite and blood sugar. But, GLP-1 receptors are also found in brain regions associated with reward, motivation, and impulse control, including the hypothalamus and the ventral tegmental area. By activating these receptors, GLP-1 agonists may modulate the brain’s reward pathways, potentially diminishing the intense cravings and compulsive behaviors characteristic of addiction. Researchers hypothesize that promoting satiety and altering dopamine signaling could reduce the reinforcing effects of addictive substances and behaviors.
Obesity Rates and the Rise of GLP-1 Medications
The increasing prevalence of GLP-1 drugs coincides with a notable shift in U.S. Obesity rates. According to a Gallup National Health and Well-Being Index survey, the obesity rate has dropped to 37% of U.S. Adults this year, down from a high of 39.9% three years ago. NPR reported on this decline in October 2025, noting that the number of Americans taking drugs like semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro) for weight loss more than doubled between February 2024 and the present, reaching 12.4% of respondents.
Challenges and Future Research
Despite the promising early signs, experts emphasize the need for further research. Clinical trials are crucial to definitively establish efficacy, determine optimal dosing strategies, understand long-term effects, and identify potential contraindications or side effects specific to addiction treatment. The pharmaceutical industry and research institutions are actively pursuing these investigations, seeking to determine whether GLP-1 agonists can become a legitimate tool in the comprehensive management of addiction.
Concerns regarding the safety and regulation of GLP-1 medications have also emerged. A report from KING5.com details allegations that a Kirkland, Washington-based startup pharmacy was hiring unlicensed workers to handle these medications, raising questions about proper dispensing and patient safety.
What This Means for Addiction Treatment
If validated, these findings could profoundly impact addiction treatment, offering a new pharmacological approach to a condition that often proves resistant to traditional therapies. The journey from observing an unexpected side effect to developing a new class of addiction treatments is complex, but the early evidence suggests that drugs like Ozempic might unlock new avenues of recovery for many. The New Yorker Radio Hour, a co-production of WNYC Studios and The New Yorker, continues to explore these cutting-edge topics.
The next step in understanding the potential of GLP-1 drugs for addiction treatment will be the results of ongoing and planned clinical trials. Researchers are actively recruiting participants for studies investigating the efficacy of semaglutide and other GLP-1 agonists in treating various forms of addiction, including alcohol leverage disorder, opioid addiction, and gambling addiction. Updates on these trials can be found on ClinicalTrials.gov.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this emerging research? Share your comments below, and please share this article with anyone who might find it informative.
Keep reading
